Published in Afr Health Sci on September 01, 2005
Willingness to participate in biomedical HIV prevention studies after the HVTN 503/Phambili trial: a survey conducted among adolescents in Soweto, South Africa. J Acquir Immune Defic Syndr (2011) 0.97
Conceptual framework for behavioral and social science in HIV vaccine clinical research. Vaccine (2011) 0.89
An assessment of fishing communities around Lake Victoria, Uganda, as potential populations for future HIV vaccine efficacy studies: an observational cohort study. BMC Public Health (2014) 0.81
An Evaluation of Selected Populations for HIV-1 Vaccine Cohort Development in Nigeria. PLoS One (2016) 0.75
Development of a prospective cohort of HIV Exposed Sero-Negative (HESN) individuals in Jos Nigeria. BMC Infect Dis (2016) 0.75
Adolescent sexual behavior, drug use, and violence: increased reporting with computer survey technology. Science (1998) 25.53
Gender-based violence, relationship power, and risk of HIV infection in women attending antenatal clinics in South Africa. Lancet (2004) 11.28
Methodological problems in AIDS behavioral research: influences on measurement error and participation bias in studies of sexual behavior. Psychol Bull (1990) 11.25
Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial. Lancet (1999) 8.91
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
Research and informed consent in Africa--another look. N Engl J Med (1992) 4.82
Reliability and validity of self-report measures of HIV-related sexual behavior: progress since 1990 and recommendations for research and practice. Arch Sex Behav (1998) 4.81
'I think condoms are good but, aai, I hate those things': condom use among adolescents and young people in a Southern African township. Soc Sci Med (2001) 4.67
Interview Mode and Measurement of Sexual Behaviors: Methodological Issues. J Sex Res (1999) 3.09
Effect of computer-assisted self-interviews on reporting of sexual HIV risk behaviours in a general population sample: a methodological experiment. AIDS (2001) 3.03
A comparison of the reliability of self-reported drug use and sexual behaviors using computer-assisted versus face-to-face interviewing. AIDS Educ Prev (2000) 3.02
Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco. Science (1994) 2.98
School-based HIV prevention programmes for African youth. Soc Sci Med (2004) 2.79
Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol (2001) 2.69
Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States. AIDS (1998) 2.53
Willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial. J Acquir Immune Defic Syndr (2002) 2.02
Reliability and validity of survey data on sexual behaviour. Health Transit Rev (1994) 2.02
Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.88
Is audio computer-assisted self-interviewing a feasible method of surveying in Zimbabwe? Int J Epidemiol (2000) 1.70
Who will enroll? Predicting participation in a phase II AIDS vaccine trial. J Acquir Immune Defic Syndr (2001) 1.66
HIV/AIDS treatment and HIV vaccines for Africa. Lancet (2002) 1.58
Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? Lancet (2000) 1.57
An STD/HIV prevention intervention framework. AIDS Patient Care STDS (2000) 1.50
Social aspects of AIDS-related stigma in rural Uganda. Health Place (1997) 1.50
Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet Infect Dis (2004) 1.46
Strategies for addressing the social and behavioral challenges of prophylactic HIV vaccine trials. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.44
Heterosexual transmission of HIV. AIDS (1988) 1.43
Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three U.S. communities. J Acquir Immune Defic Syndr (2001) 1.43
Candidate HIV/AIDS vaccines: lessons learned from the World's first phase III efficacy trials. AIDS (2003) 1.40
Development of an AIDS vaccine: perspective from the South African AIDS Vaccine Initiative. BMJ (2004) 1.39
The global HIV/AIDS pandemic, structural inequalities, and the politics of international health. Am J Public Health (2002) 1.34
Assessment of the changing willingness to participate in phase III HIV vaccine trials among men who have sex with men. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.34
Trends in HIV-1 incidence in a cohort of prostitutes in Kenya: implications for HIV-1 vaccine efficacy trials. J Acquir Immune Defic Syndr (2000) 1.33
Readiness for HIV vaccine trials: changes in willingness and knowledge among high-risk populations in the HIV network for prevention trials. The HIVNET Vaccine Preparedness Study Protocol Team. J Acquir Immune Defic Syndr (2000) 1.33
Condom use and sexual behaviors among individuals procuring free male condoms in South Africa: a prospective study. Sex Transm Dis (2002) 1.30
Incentives and disincentives to participate in prophylactic HIV vaccine research. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.29
Epidemiology of HIV infection in Africa. J Acquir Immune Defic Syndr (1988) 1.23
Audio-CASI vs interview method of administration of an HIV/STD risk of exposure screening instrument for teenagers. Int J STD AIDS (2002) 1.22
Ethical, behavioral, and social aspects of HIV vaccine trials in developing countries. JAMA (1994) 1.19
Trial-related discrimination in HIV vaccine clinical trials. AIDS Res Hum Retroviruses (2001) 1.19
Lack of increased HIV risk behavior among injection drug users participating in the AIDSVAX B/E HIV vaccine trial in Bangkok, Thailand. AIDS (2004) 1.18
Retaining hard-to-reach women in HIV prevention and vaccine trials: Project ACHIEVE. Am J Public Health (2001) 1.17
Debt crisis, health and health services in Africa. Soc Sci Med (1990) 1.17
Willingness to participate in HIV-1 vaccine trials among young Thai men. Sex Transm Infect (2000) 1.17
Knowledge about vaccine trials and willingness to participate in an HIV/AIDS vaccine study in the Ugandan military. J Acquir Immune Defic Syndr (2001) 1.16
Privacy effects on self-reported drug use: interactions with survey mode and respondent characteristics. NIDA Res Monogr (1997) 1.13
Feasibility and suitability of targeting young gay men for HIV vaccine efficacy trials. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 1.12
Factors related to the willingness of young gay men to participate in preventive HIV vaccine trials. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 1.11
Acceptability of HIV vaccine trials in high-risk heterosexual cohorts in Mombasa, Kenya. AIDS (1995) 1.10
Willingness to participate in HIV-1 vaccine efficacy trials and the effect of media events among gay and bisexual men in New York City: Project ACHIEVE. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.07
Taking informed consent seriously in global HIV vaccine research. J Acquir Immune Defic Syndr (2003) 1.06
NIH conference. HIV vaccine development: a progress report. Ann Intern Med (1994) 1.02
Sexual partner reductions explain human immunodeficiency virus declines in Uganda: comparative analyses of HIV and behavioural data in Uganda, Kenya, Malawi, and Zambia. Int J Epidemiol (2004) 1.00
Using Touch Screen Audio-CASI to Obtain Data on Sensitive Topics. Comput Human Behav (2001) 1.00
Behavioral research contributions to planning and conducting HIV vaccine efficacy studies. AIDS Res Hum Retroviruses (1994) 0.99
Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand. AIDS (1995) 0.98
HIV vaccines: a global perspective. Curr Mol Med (2003) 0.97
Preparations for AIDS vaccine trials. Retention, behavior change, and HIV-seroconversion among injecting drug users (IDUs) and sexual partners of IDUs. AIDS Res Hum Retroviruses (1994) 0.92
Feasibility and cohort development for HIV vaccine trials in Haiti. AIDS Res Hum Retroviruses (1994) 0.92
HIV Vaccine Trial participation in South Africa - an ethical assessment. J Med Philos (2002) 0.89
Evaluation of attitude, risk behavior and expectations among Thai participants in Phase I/II HIV/AIDS vaccine trials. J Med Assoc Thai (2003) 0.89
Developing AIDS vaccine trials educational programs in Uganda. J Acquir Immune Defic Syndr (2001) 0.87
Willingness to participate in HIV vaccine trials among men who have sex with men in Rio de Janeiro, Brazil. Projeto Praça Onze Study Group. J Acquir Immune Defic Syndr (2000) 0.87
Young adults and HIV vaccine: determinants of the intention of getting immunized. Can J Public Health (2001) 0.87
Social and behavioral issues in phase III HIV preventive vaccine trials. AIDS (1995) 0.85
Preparatory studies for possible HIV vaccine trials in northern Thailand. AIDS Res Hum Retroviruses (1994) 0.84
HIV vaccines: the Uganda experience. Vaccine (2002) 0.83
The decision to enroll in HIV vaccine efficacy trials: concerns elicited from gay men at increased risk for HIV infection. AIDS Res Hum Retroviruses (1994) 0.82
Future access to HIV vaccines. Report from a WHO-UNAIDS Consultation, Geneva, 2-3 October 2000. AIDS (2001) 0.82
Willingness to participate in South African HIV vaccine trials--concerns of medical professionals in the Western Cape. S Afr Med J (2002) 0.82
HIV vaccine trials in South Africa--some ethical considerations. S Afr Med J (2000) 0.81
Evaluation of behavioral and social issues among Thai HIV vaccine trial volunteers. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 0.81
Preparations for AIDS vaccine trials. Developing brief valid screening instruments for HIV-related sexual risk behavior among gay and bisexual men. AIDS Res Hum Retroviruses (1994) 0.80
The role of prevention research in HIV vaccine trials. AIDS Res Hum Retroviruses (1994) 0.80
Heterosexual transmission of HIV: a global view a decade later. Int J STD AIDS (1994) 0.79
Gender and health analysis of sexual behaviour in south-western Nigeria. Afr J Reprod Health (2003) 0.79
Barriers to accessing free condoms at public health facilities across South Africa. S Afr Med J (2002) 0.78
Gender and HIV / AIDS: transforming prevention programs. Aidscaptions (1995) 0.76
Women sex workers and the HIV pandemic: stigma and blame in context. SAfAIDS News (1997) 0.76
Informed consent and transcultural research. S Afr Med J (1995) 0.76
Vaccine efficacy trials for human immunodeficiency virus/acquired immunodeficiency syndrome are feasible in the United States: a commentary on the HIVNET Vaccine Preparedness Study. Am J Epidemiol (2001) 0.76
HIV preventive vaccine research: selected ethical issues. J Med Philos (1994) 0.76
Another condom uproar in Uganda. New Afr (1991) 0.76
Participation of homosexual/bisexual men in preventive HIV vaccine trials: baseline attitudes and concerns and predicted behaviors during trials. AIDS Res Hum Retroviruses (1994) 0.76
Preparations for AIDS vaccine trials. Recruitment and retention of in- and out-of-treatment injection drug users. AIDS Res Hum Retroviruses (1994) 0.76
Overview: HIV vaccine feasibility studies. AIDS Res Hum Retroviruses (1994) 0.76
South African faces an AIDS crisis as government health campaigns fail. Lancet (1999) 0.75
Commentary: the social pathology of the HIV/AIDS pandemic. Int J Epidemiol (2003) 0.75
Medical ethics. No consensus on rules for AIDS vaccine trials. Science (1998) 0.75
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet (2006) 31.79
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med (2015) 15.06
Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS (2008) 13.25
Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS (2005) 11.25
Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis (2006) 9.25
Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ (2008) 8.70
Grand challenges in global mental health. Nature (2011) 8.40
Use of mental health services for anxiety, mood, and substance disorders in 17 countries in the WHO world mental health surveys. Lancet (2007) 8.24
Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis (2011) 7.23
Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS (2005) 6.83
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis (2008) 6.73
Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis (2005) 6.59
Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet (2002) 6.54
Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's World Mental Health Survey Initiative. World Psychiatry (2007) 6.46
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med (2012) 6.29
Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J (2006) 6.29
Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet (2010) 6.02
Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med (2006) 5.73
Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis (2006) 5.68
Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS (2003) 5.52
Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS (2007) 5.41
Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet (2010) 5.41
Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health (2008) 5.32
Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis (2007) 5.32
Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med (2011) 5.06
Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS (2010) 4.68
When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31
Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med (2011) 4.29
Scaling up mHealth: where is the evidence? PLoS Med (2013) 4.14
"Life is still going on": reproductive intentions among HIV-positive women and men in South Africa. Soc Sci Med (2007) 4.14
Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS (2009) 4.07
Toward a global view of alcohol, tobacco, cannabis, and cocaine use: findings from the WHO World Mental Health Surveys. PLoS Med (2008) 4.01
High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis (2008) 3.92
Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS (2009) 3.91
Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis (2009) 3.77
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis (2011) 3.71
Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther (2007) 3.60
Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med (2008) 3.56
Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa. PLoS One (2010) 3.48
CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr (2006) 3.39
Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS (2008) 3.31
Fertility intentions and reproductive health care needs of people living with HIV in Cape Town, South Africa: implications for integrating reproductive health and HIV care services. AIDS Behav (2009) 3.29
Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther (2007) 3.27
Setting priorities for global mental health research. Bull World Health Organ (2009) 3.26
Common mental disorders among HIV-infected individuals in South Africa: prevalence, predictors, and validation of brief psychiatric rating scales. AIDS Patient Care STDS (2008) 3.24
Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS (2005) 3.16
Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients. Proc Natl Acad Sci U S A (2003) 3.14
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis (2009) 3.05
Research capacity. Enabling the genomic revolution in Africa. Science (2014) 3.05
Development of lifetime comorbidity in the World Health Organization world mental health surveys. Arch Gen Psychiatry (2011) 3.01
Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med (2005) 3.01
Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun (2003) 3.01
Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop Med Int Health (2009) 2.99
Outcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration. S Afr Med J (2009) 2.97
Loss to follow-up and mortality among pregnant women referred to a community clinic for antiretroviral treatment. AIDS (2008) 2.96
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96
Mental disorders among persons with chronic back or neck pain: results from the World Mental Health Surveys. Pain (2007) 2.95